Update your treatment options with this thought-leader discussion, with associated slide deck and eNewsflash, featuring valuable updates and expert perspectives on exciting new developments in the management of breast cancer released at the 2017 Annual Breast Cancer Meeting in San Antonio.
Dec 12, 2017
Dec 12, 2018
Abstract #GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial
Abstract #P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
Abstract #P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies
Abstract #P1-17-03: Abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive breast cancer
Abstract #GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
Abstract #P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study
Abstract #P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment
Abstract #P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)t
Abstract #GS2-07: MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer
Abstract #GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Nadia Harbeck, MD, PhDUniversity of Munich
Yen-Shen Lu, MDNational Taiwan University
Ahmed Saadeddin, MD, FRCRKing Abdulaziz Medical City
Riyadh, Kingdom of Saudi Arabia
After successful completion of this educational activity, participants should be able to:
- Summarize the clinical application of novel combinations of targeted and endocrine therapy for the first- and second-line treatment of ER-positive, HER2-negative advanced breast cancer
- Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options
This educational activity is supported by a grant from Novartis Pharma AG.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This enduring activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.